News | June 15, 2022
CCI approves sale of biosimilars portfolio of Viatris to Biocon Biologics
The proposed transaction involves the sale of the global biosimilars portfolio of Viatris to Biocon Biologics
The proposed transaction involves the sale of the global biosimilars portfolio of Viatris to Biocon Biologics
Abevmy follows the launch of the company’s two oncology biosimilars in Canada, Ogivri (bTrastuzumab) in 2019 – the first Trastuzumab approved in the country – and Fulphila (bPegfilgrastim), which was launched in 2020
The inspection report contains no 'critical' observations and only one of the deficiencies is categorized as 'major' which is being addressed expeditiously in consultation with the regulatory agency
Biocon Biologics’ Insugen formulations will be available to patients at all Ministry of Health hospitals, district health offices and health clinics
Celerity Pharmaceuticals uses Biocon Biologics’ insulin drug substance to develop the product
BBL will gain Viatris’ global biosimilars business whose revenues are estimated to be USD 1 billion next year, along with its portfolio of in-licensed biosimilar assets
Branded and unbranded versions of the first-ever interchangeable biosimilar in the U.S. provide more affordable options for the millions of Americans living with diabetes
BRIDGE-1 Comprehensive care programme for Type 1 diabetes and to train 400 physicians and benefit over 1000 children
Express Scripts, a leading pharmacy benefit management organization, will list Viatris labelled biosimilar insulin Glargine as a preferred insulin brand on its National Preferred Formulary (NPF)
The company does not expect the outcome of this inspection to impact its plans
Subscribe To Our Newsletter & Stay Updated
